[Cardiac tolerance of the combination paclitaxel-anthracyclines in the context of the management of cancer of the breast].
Within the past decades there has been major interest in associating the paclitaxel into the management of breast cancer patients with a strong improvement of clinical results. Moreover, doxorubicin is historically one of the major chemotherapeutic agents in breast cancer treatment. So, investigations of the combination of the paclitaxel with doxorubicin have logically taken place in the strategy of breast cancer management. Also, this association became a standard of care neoadjuvantly in locally advanced breast cancer. The aim of this review of literature consists to make a special focus on cardiac toxicity occurring after doxorubicin and paclitaxel association and to give adequate directions for the next future in this promising combination.
Ferrero
Jean-Marc
JM
Département d'oncologie médicale, Centre Antoine-Lacassagne, 33, avenue de Valombrose, 06189 Nice, Institut Jules-Bordet, 121 boulevard de Waterloo, 1000 Bruxelles, Belgique.
Magné
Nicolas
N
Foa
Cyril
C
Largillier
Rémy
R
Namer
Moïse
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006321:Heart / Q000187:drug effects*; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects
D004317:Doxorubicin; D017239:Paclitaxel